De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Biosynex Balans Gezondheid

Financiële gezondheid criteriumcontroles 3/6

Biosynex heeft een totaal eigen vermogen van €124.3M en een totale schuld van €64.1M, wat de schuld-eigenvermogensverhouding op 51.6% brengt. De totale activa en totale passiva bedragen respectievelijk €241.7M en €117.4M.

Belangrijke informatie

51.6%

Verhouding schuld/eigen vermogen

€64.12m

Schuld

Rente dekkingsratio	n/a
Contant	€26.16m
Aandelen	€124.32m
Totaal verplichtingen	€117.41m
Totaal activa	€241.73m

Recente financiële gezondheidsupdates

Biosynex (EPA:ALBIO) Could Easily Take On More Debt

Jun 23

We Think Biosynex (EPA:ALBIO) Can Stay On Top Of Its Debt

Dec 19

Recent updates

Biosynex SA's (EPA:ALBIO) Shares Bounce 28% But Its Business Still Trails The Industry

Aug 16

Biosynex SA (EPA:ALBIO) Not Doing Enough For Some Investors As Its Shares Slump 30%

Jun 29

Biosynex SA (EPA:ALBIO) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Mar 12

Biosynex SA's (EPA:ALBIO) Shares Not Telling The Full Story

Jan 20

Returns On Capital Are Showing Encouraging Signs At Biosynex (EPA:ALBIO)

May 05

Investors Shouldn't Overlook Biosynex's (EPA:ALBIO) Impressive Returns On Capital

Dec 01

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( €91.4M ) ALBIO } overtreffen de korte termijn passiva ( €40.8M ).

Langlopende schulden: De kortetermijnactiva ALBIO ( €91.4M ) overtreffen de langetermijnschulden ( €76.6M ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: De netto schuld/eigen vermogen ratio ( 30.5% ) ALBIO wordt als voldoende beschouwd.

Schuld verminderen: De schuld/eigen vermogen-ratio van ALBIO is de afgelopen 5 jaar gestegen van 17.7% naar 51.6%.

Schuldendekking: De operationele kasstroom van ALBIO is negatief, waardoor de schuld niet goed gedekt is.

Rentedekking: Er zijn onvoldoende gegevens om te bepalen of de rentebetalingen van ALBIO op haar schulden goed worden gedekt door EBIT.

Biosynex Balans Gezondheid

Financiële gezondheid criteriumcontroles 3/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Biosynex (EPA:ALBIO) Could Easily Take On More Debt

We Think Biosynex (EPA:ALBIO) Can Stay On Top Of Its Debt

Recent updates

Biosynex SA's (EPA:ALBIO) Shares Bounce 28% But Its Business Still Trails The Industry

Biosynex SA (EPA:ALBIO) Not Doing Enough For Some Investors As Its Shares Slump 30%

New major risk - Share price stability

Biosynex SA, Annual General Meeting, Jun 07, 2024

Full year 2023 earnings released: €3.45 loss per share (vs €1.53 profit in FY 2022)

Biosynex SA (EPA:ALBIO) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny

New minor risk - Shareholder dilution

Biosynex SA's (EPA:ALBIO) Shares Not Telling The Full Story

First half 2023 earnings released: €1.94 loss per share (vs €2.99 profit in 1H 2022)

New minor risk - Market cap size

New major risk - Earnings quality

Biosynex SA (ENXTPA:ALBIO) acquired 57.33% interest in ProciseDx Inc. from Nestlé HealthCare Nutrition, Inc., other shareholders, employees, former employees and investors.

Biosynex SA (ENXTPA:ALBIO) signed an agreement to acquire 57.33% interest in ProciseDx Inc. from Nestlé HealthCare Nutrition, Inc., other shareholders, employees, former employees and investors.

Biosynex SA (ENXTPA:ALBIO) acquired Eye Care activity from LABORATOIRES INNOXA.

Investor sentiment improves as stock rises 16%

Returns On Capital Are Showing Encouraging Signs At Biosynex (EPA:ALBIO)

Investor sentiment deteriorates as stock falls 22%

Full year 2022 earnings released

Biosynex SA (ENXTPA:ALBIO) entered into a definitive merger agreement to acquire Chembio Diagnostics, Inc. (NasdaqCM:CEMI) for $17.2 million.

Investor sentiment improved over the past week

Biosynex SA (ENXTPA:ALBIO) acquired 75% stake in Medkoncept A/S.

Investors Shouldn't Overlook Biosynex's (EPA:ALBIO) Impressive Returns On Capital

Investor sentiment improved over the past week

No independent directors

First half 2022 earnings released

Biosynex SA (ENXTPA:ALBIO) acquired Doc2u SAS on October 12, 2022.

Biosynex (EPA:ALBIO) Could Easily Take On More Debt

Biosynex SA (ENXTPA:ALBIO) alongside the two founders acquired Bhr Pharmaceuticals Limited.

Upcoming dividend of €2.00 per share

Full year 2021 earnings released: EPS: €10.08 (vs €3.52 in FY 2020)

No independent directors

Biosynex SA (ENXTPA:ALBIO) acquired PrimaDiag SAS.

Biosynex SA (ENXTPA:ALBIO) acquired Para'kito.

Full year 2021 earnings released

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Biosynex SA (ENXTPA:ALBIO) signed a binding letter of offer to acquire Human Health Business of Enalees.

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

If You Like EPS Growth Then Check Out Biosynex (EPA:ALBIO) Before It's Too Late

Biosynex SA (ENXTPA:ALBIO) commences an Equity Buyback Plan for 10% of its issued share capital, for €4.5 million, under the authorization approved on June 8, 2020.

Here's Why I Think Biosynex (EPA:ALBIO) Is An Interesting Stock

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Biosynex SA has completed a Follow-on Equity Offering in the amount of €15 million.

Investor sentiment deteriorated over the past week

New 90-day high: €20.60

Investor sentiment improved over the past week

We Think Biosynex (EPA:ALBIO) Can Stay On Top Of Its Debt

Market bids up stock over the past week

Market pulls back on stock over the past week

New 90-day high: €19.90

First half earnings released

New 90-day high: €13.50

New 90-day high: €12.50

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Ontdek gezonde bedrijven